FYX's Core Assets Suggest Potential for 11% Increase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 23 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Price: The First Trust Small Cap Core AlphaDEX Fund ETF (FYX) has an implied analyst target price of $122.32, indicating a potential upside of 10.92% from its current trading price of $110.28.
Notable Holdings with Upside: Key underlying holdings of FYX, such as Distribution Solutions Group Inc (DSGR), Clover Health Investments Corp (CLOV), and Vital Farms Inc (VITL), show significant upside potential based on analyst target prices, with expected increases of 23.32%, 21.67%, and 20.01% respectively.
Analyst Views on CLOV
Wall Street analysts forecast CLOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLOV is 3.35 USD with a low forecast of 3.00 USD and a high forecast of 3.70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.620
Low
3.00
Averages
3.35
High
3.70
Current: 2.620
Low
3.00
Averages
3.35
High
3.70
About CLOV
Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
